June 22, 2018 / 5:08 AM / 5 months ago

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

June 22 (Reuters) - Santhera Pharmaceuticals Holding AG:

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below